Published in J Neural Transm (Vienna) on February 19, 2007
Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome. Tech Coloproctol (2014) 1.02
Age and sex effects on 5-HT(4) receptors in the human brain: a [(11)C]SB207145 PET study. J Cereb Blood Flow Metab (2011) 0.85
Reorganisation of brain networks in frontotemporal dementia and progressive supranuclear palsy. Neuroimage Clin (2013) 0.83
An immunohistochemical study of the serotonin 1A receptor in the hippocampus of subjects with Alzheimer's disease. Neuropathology (2011) 0.80
Factors associated with a depressive disorder in Alzheimer's disease are different from those found for other dementia disorders. Dement Geriatr Cogn Dis Extra (2012) 0.78
Localization of 5-HT1A and 5-HT2A positive cells in the brainstems of control age-matched and Alzheimer individuals. Age (Dordr) (2010) 0.77
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (1975) 301.74
Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res (1983) 41.26
Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage (2002) 3.88
Posterior cingulate cortex in Alzheimer's disease. Lancet (1994) 2.11
Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. Am J Psychiatry (2003) 1.77
A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT1A receptor binding in humans. J Neurosci (2005) 1.77
Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer's disease prospectively assessed for behavioural changes. Neuropathol Appl Neurobiol (2000) 1.63
Role of serotonin in memory impairment. Ann Med (2000) 1.62
Multicompartmental study of fluorine-18 altanserin binding to brain 5HT2 receptors in humans using positron emission tomography. Eur J Nucl Med (1994) 1.42
Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc Natl Acad Sci U S A (2006) 1.34
Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study. Acta Neurol Scand (1992) 1.29
Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease. J Neurochem (1983) 1.28
Nucleus raphe dorsalis in Alzheimer's disease: neurofibrillary tangles and loss of large neurons. Ann Neurol (1985) 1.25
Predominant ventromedial frontopolar metabolic impairment in frontotemporal dementia. Neuroimage (2003) 1.23
Frontal lobe dysfunction in amyotrophic lateral sclerosis. A PET study. Brain (1996) 1.21
Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration. Ann Neurol (2005) 1.17
Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord (2004) 1.15
Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol (2003) 1.14
Human brain serotonin synthesis capacity measured in vivo with alpha-[C-11]methyl-L-tryptophan. Synapse (1998) 1.13
Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry (1997) 1.11
Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia (2005) 1.10
Presynaptic serotonergic dysfunction in patients with Alzheimer's disease. J Neurochem (1987) 1.09
Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl) (2003) 1.06
Monoamine neurons in aging and Alzheimer's disease. J Neural Transm Gen Sect (1993) 1.06
A database of [(18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: normative data and relationship to physiological and demographic variables. Neuroimage (2004) 1.03
Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. Am J Psychiatry (2000) 1.02
5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. Hum Mol Genet (1998) 1.00
Complex compulsive behaviour in the temporal variant of frontotemporal dementia. J Neurol (2001) 0.98
Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients. BMC Neurosci (2006) 0.97
Neuropathological study of the dorsal raphe nuclei in late-life depression and Alzheimer's disease with and without depression. Am J Psychiatry (2004) 0.96
In vivo binding properties of [carbonyl-11C]WAY-100635: effect of endogenous serotonin. Synapse (2001) 0.94
Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. Brain Res (2003) 0.94
Distribution of serotonin receptors. Ann N Y Acad Sci (1990) 0.93
Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction. Brain Res (1998) 0.92
PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am J Psychiatry (1999) 0.91
[11C]WAY 100635: a radioligand for imaging 5-HT1A receptors with positron emission tomography. Life Sci (1994) 0.91
Neurochemical features of frontotemporal dementia. Dement Geriatr Cogn Disord (1999) 0.90
Comparison of impaired subcortico-frontal metabolic networks in normal aging, subcortico-frontal dementia, and cortical frontal dementia. Neuroimage (1999) 0.90
Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. J Nucl Med (1991) 0.89
Reduced binding of [3H]ketanserin to cortical 5-ht2 receptors in senile dementia of the Alzheimer type. Neurosci Lett (1984) 0.89
Studies on neurotransmitter receptor systems in neocortex and hippocampus in senile dementia of the Alzheimer-type. J Neurol Sci (1984) 0.89
[11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS. Brain (2005) 0.88
Frontotemporal dementia: evidence for impairment of ascending serotoninergic but not noradrenergic innervation. Immunocytochemical and quantitative study using a graph method. Acta Neuropathol (2001) 0.87
A study of the serotonin transporter in the prefrontal cortex in late-life depression and Alzheimer's disease with and without depression. Neuropathol Appl Neurobiol (2006) 0.86
Imaging of the 5-HT2A system: age-, gender-, and Alzheimer's disease-related findings. Neurobiol Aging (2003) 0.86
Imaging of serotonin and dopamine transporters in the living human brain. Eur J Nucl Med (1995) 0.84
Brain stem serotonin-synthesizing neurons in Alzheimer's disease: a clinicopathological correlation. Acta Neuropathol (1992) 0.84
Loss of brain 5-HT2 receptors in Alzheimer's disease. In vivo assessment with positron emission tomography and [18F]setoperone. Brain (1993) 0.84
The 5-HTTPR*S/*L polymorphism and aggressive behavior in Alzheimer disease. Arch Neurol (2001) 0.83
Binding characteristics of the 5-HT2A receptor antagonists altanserin and MDL 100907. Synapse (2005) 0.83
Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging. Psychiatry Res (1996) 0.83
Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease. Psychopharmacology (Berl) (2004) 0.82
Pindolol occupancy of 5-HT(1A) receptors measured in vivo using small animal positron emission tomography with carbon-11 labeled WAY 100635. Synapse (2000) 0.82
In vivo delineation of 5-HT1A receptors in human brain with [18F]MPPF. J Nucl Med (2000) 0.81
Neuropathology of aminergic nuclei in Alzheimer's disease. Prog Clin Biol Res (1989) 0.81
Localization of serotonin 5-HT2 receptors in living human brain by positron emission tomography using N1-([11C]-methyl)-2-Br-LSD. Synapse (1987) 0.81
Association between 5-HT(2A) receptor polymorphism and psychotic symptoms in Alzheimer's disease. Biol Psychiatry (2001) 0.80
Occupancy of 5-HT1A receptors by clozapine in the primate brain: a PET study. Psychopharmacology (Berl) (2003) 0.80
PET measurement of neuroreceptor occupancy by typical and atypical neuroleptics. J Nucl Med (1996) 0.79
Age-related reduction of [11C]MDL100,907 binding to central 5-HT(2A) receptors: PET study in the conscious monkey brain. Brain Res (2000) 0.77
Fluoxetine in Alzheimer's disease with severe obsessive compulsive symptoms and a low density of serotonin transporter sites. Pharmacopsychiatry (2003) 0.77
[(18)F]p-MPPF: aA radiolabeled antagonist for the study of 5-HT(1A) receptors with PET. Nucl Med Biol (2000) 0.76
Imaging serotonin transporters with 123I-ADAM brain SPECT in healthy non-human primates. Nucl Med Commun (2004) 0.76
Behavioral effects of trazodone in Alzheimer's disease. J Clin Psychiatry (1994) 0.75
Quantification of baboon cortical S2 serotonin receptors in vivo with 3-N-(2'-F18)fluoroethylspiperone and positron emission tomography. Eur J Nucl Med (1991) 0.75